Atcor Medical : Positive Novartis drug trial using SphygmoCor XCEL

ASX release 23 January 2017

AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system for advanced hypertension management, today announced the publication of the Novartis Pharmaceuticals Corporation's PARAMETER study1 in the influential journal Hypertension. The purpose of this study was to determine the effectiveness of its new drug in reducing central aortic systolic

pressure (CASP) in elderly patients, which was the primary end point and measured using SphygmoCor XCEL.

The randomised controlled trial examined 454 multi-ethnic elderly patients with systolic hypertension (high blood pressure) at 48 sites in 12 countries and determined that the new drug compound, sacubitril/valsartan was more effective than the currently used drug, olmesartan, in reducing CASP and central aortic pulse pressure (CAPP) within the trial period (p=0.01).

The authors stated: "The magnitude of BP reduction achieved [in this study] has previously been shown to have a major beneficial impact on cardiovascular outcomes, stroke, and heart failure in patients with systolic hypertension." They further stated: "The PARAMETER study, for the first time, shows the effect of sacubitril/valsartan on central aortic pressures and demonstrates the superiority of sacubitril/valsartan in lowering CASP and CAPP compared with RAS blockade with the ARB olmesartan, after 12- week treatment."

AtCor Medical chief executive officer, Duncan Ross, said: "We have worked closely with Novartis on a number of its trials over the years. It is pleasing to see positive results that will lead to better outcomes for at-risk patients, further demonstrating the clinical benefit of utilising SphygmoCor in patient management including drug selection and dosing."

AtCor Medical develops and markets products for the early detection of target organ damage and management of cardiovascular and renal disease. Its technology allows researchers and clinicians to noninvasively measure the central arterial pressure waveform, central aortic pressures and pulse wave velocity. Central arterial pressure waveform analysis, as measured by the company's SphygmoCor system, provides clinicians with better prognostic and diagnostic information to determine the need for and type of interventions, effects which cannot be detected with standard brachial blood pressure measurements. SphygmoCor is essential for hypertension management.

1 Bryan Williams et.al, Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly with Systolic Hypertension: The PARAMETER Study, Hypertension. 2017;69:00-00

More than 4,000 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 1,000 peer-reviewed studies published in leading medical journals and thousands of citations. AtCor Medical has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com.

For further information, please contact:

Duncan Ross - AtCor Medical CEO

+1 (630) 228 8873

Peter Manley - AtCor Medical CFO

+61 (2) 8815 8811

Media enquiries to:

Ashley Rambukwella - Financial & Corporate Relations

Ph: +61 (2) 8264 1004/ m. 0407 231 282 or

a.rambukwella@fcr.com.au